Defiance ETFs introduced the Defiance Daily Target 2X Long MRNA ETF (ticker MRNX) on February 4, 2026. The fund is designed to deliver 200 % of the daily percentage change in Moderna’s share price, giving traders amplified short‑term exposure to the mRNA biotechnology company.
Leveraged ETFs use derivatives to achieve their daily objectives, and the MRNX’s 2X leverage means that a 1 % move in Moderna’s stock translates into a 2 % move in the ETF’s value. The daily rebalancing that underpins this strategy also creates a “volatility drag” that can erode returns over periods longer than a single trading day, making the product suitable only for active, short‑term investors rather than long‑term holders.
Moderna’s recent performance provides context for the new ETF. In Q3 2025 the company reported earnings of –$0.51 per share on revenue of $1.02 billion, a beat on revenue expectations but a loss on earnings. The company is pursuing a diversified pipeline that includes respiratory vaccines, oncology therapeutics, and rare‑disease treatments, while working to reduce cash burn and reach cash breakeven by 2028.
Defiance’s launch of MRNX fits into its broader strategy of offering thematic, income, and leveraged ETFs. By adding a single‑stock leveraged product that tracks a high‑profile biotech, the firm expands its lineup and provides traders with a new tool to express views on Moderna’s short‑term price movements.
The MRNX launch offers a new vehicle for traders seeking amplified exposure to Moderna, but the leveraged structure and daily rebalancing mean that the product carries significant risk. Investors should be aware that the fund is not designed for long‑term investment and that volatility can erode returns over time.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.